Loading stock data…
EW
$82.85-0.06 (-0.07%)
Market OpenUpdated 10:15 AM EDT
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Edwards Lifesciences Corporation in the Healthcare sector is trading at $82.85. The stock is currently 6% below its 52-week high of $87.89, remaining 2.1% above its 200-day moving average. Technical signals show neutral RSI of 60 and bullish MACD crossover, explaining why EW maintains its current momentum and trend strength. The Whystock Score of 65/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 60) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$82.85
Potential Downside
42.2%
Whystock Fair Value$47.86
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus27 analysts
Buy
Mean target$97.15+17.3%
Range$84.00 – $110.00
Fundamentals
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive re...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$47.35B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
45.04
Beta
Defensive asset. Lower volatility than the S&P 500.
0.94
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
40.10%
Volume
Today's trading volume
348,575
Recent News
Edwards names Theodora Mistras as CFO
Mistras, who joins the heart valve company after two years as CFO at pharmaceutical firm Viatris, also brings investment banking experience.
Possible Bearish Signals With Edwards Lifesciences Insiders Disposing Stock
Over the past year, many Edwards Lifesciences Corporation ( NYSE:EW ) insiders sold a significant stake in the company...
Top Research Reports for Philip Morris, Honeywell & Starbucks
Philip Morris, Honeywell and Starbucks stocks outperform peers as pricing power, aviation demand and turnaround efforts drive growth prospects.
Global's Undervalued Small Caps With Insider Actions For May 2026
As global markets navigate a complex landscape marked by record highs in major U.S. stock indexes, driven by robust economic data and AI-linked stocks, small-cap companies are capturing investor interest amid resilient consumer demand and evolving geopolitical tensions. In this environment, identifying promising small-cap stocks involves considering factors such as strong earnings potential and strategic insider actions that align with broader market trends.
Barclays Lifts PT on Edwards Lifesciences Corporation (EW) Following Q1 Earnings
Edwards Lifesciences Corporation (NYSE:EW) is one of the best medical device stocks to invest in right now. Barclays raised the price target on Edwards Lifesciences Corporation (NYSE:EW) to $110 from $104 on April 27, reaffirming an Overweight rating on the shares. The rating update came after the company’s fiscal Q1 earnings, with the firm telling […]